A Doylestown biotech backed by OrbiMed and Qiming is betting AI can solve one of pharma's oldest headaches: getting peptide drugs past the stomach.
Pinnacle Medicines closed an $89 million Series B round this week, the company announced, with returning investors OrbiMed and Qiming Venture Partners doubling down on a platform they first backed during the startup's Series A. Both firms hold board seats—a sign of continued conviction in what remains a notoriously difficult scientific problem.
The Doylestown, Pennsylvania-based company, which also operates a lab in Shanghai's Zhangjiang biotech hub, is chasing something the industry has pursued for decades: oral versions of peptide therapeutics that typically require injection. If successful, Pinnacle could reshape treatment for everything from asthma to obesity. If not, well, it won't be the first to stumble on the chemistry.
The Same Backers, a Bigger Bet
OrbiMed's David Wang and Diyong Xu sit on Pinnacle's board alongside Qiming's Kan Chen. Wang, according to regulatory filings published in April 2025, also serves as a director of both the company's U.S. and Chinese entities—an unusual level of involvement that suggests more than passive capital.
The two firms led what Pinnacle previously described as "substantial Series A funding," though the company never disclosed that round's size. This Series B effectively represents a promotion: early believers putting more chips on the table.
AI Meets Medicinal Chemistry
Pinnacle's pitch hinges on PinSilico, its computational platform, which the company describes as a suite of interconnected tools. PinNovo handles de novo drug design. PinFinity optimizes binding. PinFormatics manages data intelligence, and PinScale automates the compute-heavy work. Alongside that sits PinPoint, the chemistry engine, which incorporates non-canonical amino acids—building blocks not found in nature—to make peptides more drug-like.
The company's website distills the ambition into six words: "antibody-like efficacy with a pill."
That's easier said than done. Peptides tend to fall apart in the acidic environment of the gut, and even when they survive, they struggle to cross the intestinal wall into the bloodstream. Pinnacle's chemistry platform aims to sidestep both problems, though the company hasn't yet named a specific drug candidate or disclosed clinical data.
Veterans of Peptide Wars
CEO Jonathan Wang previously served as chief business officer at Zai Lab and earlier worked at OrbiMed, BCG, and Goldman Sachs—a resume that skews toward finance and dealmaking. The scientific firepower comes from co-founder and Chief Scientific Officer Chengzao Sun, who spent over two decades in peptide discovery at Amylin, Merck, and Johnson & Johnson, where he ran the Peptide Platform and Early Portfolio. CTO Sandeep Somani, also a co-founder, led oral peptide programs at J&J before joining Pinnacle.
In other words, the team has seen this movie before. Whether that's reassuring or a warning depends on your read of the sector's history.
What They're Chasing
Pinnacle is targeting a laundry list of high-value indications: asthma, COPD, inflammatory bowel disease, atopic dermatitis, obesity, and cardiovascular disease. The company also mentions undisclosed bispecific peptide programs—presumably compounds that hit two targets at once, a format that's gained traction in oncology but remains experimental in metabolic and inflammatory settings.
No lead candidates have been publicly identified, which likely means the company is still in lead optimization. That's consistent with its recent hiring spree: roles posted in recent weeks include directors and senior directors across process chemistry, bioanalytics, toxicology, machine learning, structural biology, quality assurance, and oral formulation. LinkedIn pegs the headcount between 11 and 50 employees, though that range is vague enough to accommodate significant growth—or not.
The Broader Oral Peptide Rush
Pinnacle's raise lands in the middle of what might generously be called a feeding frenzy around oral peptide platforms. AbbVie paid $200 million for Nimble Therapeutics in 2025, a deal that validated the space even if the price tag was relatively modest by recent acquisition standards. Orbis Medicines closed a €90 million Series A in January 2025 for oral macrocycles, a related but distinct approach. Circle Pharma raised $90 million in September 2024 to advance similar programs.
The Peptide Drug Hunting Council, in its fourth-quarter 2025 briefing, noted increasing consolidation and a wave of partnerships between AI-enabled peptide startups and large pharma. More clinical readouts are expected in 2026, the group said, which should clarify whether the enthusiasm is justified.
For now, though, Pinnacle is focused on the grind: advancing its pipeline through lead optimization and IND-enabling studies, expanding its computational infrastructure, and hoping the chemistry holds up. The company can be reached at [email protected], if you're inclined to inquire about the details they haven't yet disclosed.
